Publication

Article

CURE

Fall 2007
Volume6
Issue 5

Diagnosis Delay

Delayed diagnosis too common.

Experts stress the importance of catching cancer early at its most treatable stage. But in the childhood population, cancer is usually so rare that it’s often overlooked when a child initially has symptoms. The delay in diagnosis can be costly since most childhood cancers are considered fast-growing.

Researchers examined 23 studies conducted between 1976 and 2006 to find any underlying patterns that may contribute to delayed diagnosis, which included the time it took parents to take the child to a physician after symptoms appeared, and from the first health care visit to cancer diagnosis.

Findings of the study, published in August in the journal Cancer, found physician delays to be longer than parent delays in the majority of studies. Factors influencing time to diagnosis included the child’s age, parents’ education level, symptoms, cancer stage, the initial medical specialty consulted, and most significantly, the type of cancer. How those factors relate to prognosis and outcome remains unknown.

The analysis, concluded the authors, is the first step in developing new strategies and programs to shor ten the delay in diagnosis for childhood cancer patients.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of Staci.
Image of Dr. Zhaoming Wang with text.
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Image of woman with text.
Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of life, not just disease control.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Related Content